Navigation Links
Pittsburgh scientists find protein may be key to new therapies for elevated triglycerides

Diabetes researchers at the John G. Rangos Sr. Research Center at Childrens Hospital of Pittsburgh of UPMC have identified a potential target for the development of new therapies to treat hypertriglyceridemia, a lipid disorder commonly seen in people who are obese and diabetic. Results of their study are published in the June issue of the Journal of Clinical Investigation.

Scientists in the Division of Immunogenetics at Childrens Hospital studied the role of a protein known as Forkhead Box O1 (FoxO1) that mediates the metabolism of glucose and cholesterol. In the laboratory, the researchers were able to curb the secretion of triglycerides in animals that were obese and diabetic by inhibiting the production of FoxO1 in the liver. Elevated triglyceride levels have been identified as a risk factor for heart disease.

Our latest findings suggest that we may eventually be able to develop drug therapies that inhibit FoxO1, which would thereby inhibit the production of proteins that lead to elevated triglyceride levels in people who are obese and/or who suffer from type 2 diabetes, said Henry Dong, PhD, a diabetes researcher in the Division of Immunogenetics at Childrens and senior author of the study. Hypertriglyceridemia is a known risk factor for developing heart disease, the leading cause of death in the United States.

The research team was led by Dr. Dong, who has been studying the role of FoxO1 for the last seven years. Adama Kamagate, PhD, is the lead author in the study. Dr. Dong is an assistant professor of Pediatrics at the University of Pittsburgh School of Medicine.

Their research suggests that FoxO1 is vital to the regulation of a protein known as microsomal triglyceride transfer protein (MTP). MTP facilitates the production of very low-density lipoproteins (VLDL), which are produced in extreme excess in people with hypertriglyceridemia. The study found that FoxO1 mediates insulin action on the production of MTP in the liver. Augmented production of MTP, caused by the inability of insulin to regulate the activity of FoxO1, led to the overproduction of VLDL and hypertriglyceridemia in mice. Mice that were made to be deficient in FoxO1 in the liver experienced reduced MTP and VLDL production.

Having determined FoxO1s role in the liver, Childrens researchers now are studying its function in other tissues and organs to determine what an impact such therapies might have on children and adults who are obese and/or have type 2 diabetes, which put a person at risk for heart disease.


Contact: Marc Lukasiak
Children's Hospital of Pittsburgh

Related medicine news :

1. Rockin Out for Autism in Pittsburgh
2. 16th Annual Komen Pittsburgh Race for the Cure(R) Winners Announced
3. ONE YEAR Until the New Childrens Hospital of Pittsburgh of UPMC Opens in Lawrenceville
4. American Lung Association Issues State of the Air Report: First City Outside California (Pittsburgh) Tops One of the Most-Polluted Lists
5. UPMC Health Plan and Rainbow Kitchen Community Services at W.A.R. to Wipe Out Hunger in Pittsburgh
6. Creating Healing Environments: Healthcare Industrys Largest Sustainability Conference to be Held May 20-22 in Pittsburgh
7. Childrens Hospital of Pittsburgh of UPMC Involved in Projects To Develop Nations First Heart Assist Devices for Young Children
8. Pittsburghers Slow to Quit
9. Highmark, Prominent Part of Pittsburgh City Skyline, to Go Dark for One Hour to Support the Environment
10. Study validates Pittsburgh Compound-B in identifying Alzheimers disease brain toxins
11. University of Pittsburgh researchers crack code of 3-D structure in key metabolic protein
Post Your Comments:
(Date:11/26/2015)... ... November 26, 2015 , ... ... wellness consultation, has collaborated with Women’s Web – an online resource for ... topics on mental and emotional well-being relationship, life balance, stress, professional development, ...
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... ... potentially more aggressive than those found on mammography, according to a study published ... of additional cancers not seen on mammography may necessitate a change in treatment. ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... preparing the perfect dish and pleasing the palates of attendees is of the ... a dish to a seasonal get-together, give these recipes a try this holiday ...
(Date:11/25/2015)... ... November 25, 2015 , ... Medical Solutions, ... again for its stellar workplace culture with the company’s Cincinnati office being named ... Solutions’ Cincinnati office was named a finalist in Cincinnati Business Courier’s 13th annual ...
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... Dr. John ... to learn more about hair loss treatment with the Capillus272™ Pro laser therapy cap. ... solution for thicker and fuller hair, without the need for surgery, prescription pills, or ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... 2015 ... the  "2016 Future Horizons and Growth ... Monitoring (TDM) Market: Supplier Shares, Country ...  report to their offering.  --> ... addition of the  "2016 Future Horizons ...
(Date:11/26/2015)... 2015 ) ... "Radioimmunoassay Market by Type (Reagents & Kits, ... Clinical Diagnostic Labs), Application (Research, Clinical Diagnostics), ... report to their offering. --> ... of the "Radioimmunoassay Market by Type ...
(Date:11/25/2015)... OAKS, Calif. , Nov. 25, 2015  Amgen ... a Biologics License Application (BLA) with the ... (FDA) for ABP 501, a biosimilar candidate to Humira ... first adalimumab biosimilar application submitted to the FDA and ... pathway. Sean E. Harper , M.D., executive ...
Breaking Medicine Technology: